4Filing Date: Jun 11, 2026

Metlife 4: HUBBARD ROBERT GLENN bought 678 shares of Common Stock at $… (Jun 11, 2026)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001283051-26-000009
Total Value$58.0K
Trades1
Insiders1

Transaction Details

HUBBARD ROBERT GLENN
Director·Direct
Grant · Acquire
Common Stock
Shares+678
Price$85.57
Total Value$58.0K
Shares Owned After106.56K
Transaction DateJun 9, 2026
Footnotes ▸

Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Post-Transaction Holdings

HUBBARD ROBERT GLENN · Director
SecuritySharesChange
Common Stock106.56K+678 (0.64%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-06-09 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: METLIFE INC (MET) CIK: 0001099219 --- Reporting Owner --- Name: HUBBARD ROBERT GLENN CIK: 0001283051 Role: Director --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-06-09 | Code: A (Grant or award) Shares: +678 | Price: $85.57 Total Value: $58,016.46 Shares Owned After: 106,557 | Ownership: D (Direct) Footnotes: [F1] Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. --- Footnotes (Complete Index) --- F1: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. --- Signature --- /s/ /s/ Morgan Keehner-Jones Mayes, Attorney-in-fact (2026-06-11)

keid analysis is for reference only and does not constitute investment advice.